| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.28 | 6e-05 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0001 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.25 | 0.0007 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |